在威尔姆斯瘤中,阿克丁诺米辛D和博尔特佐米布破坏了蛋白质平衡
Patricia D B Tiburcio1, Kenian Chen2, Lin Xu1,2
1Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX.
bioRxiv : the preprint server for biology
|July 1, 2024
概括
无塑性威尔姆斯瘤细胞通过促进蛋白质处置来抵抗化疗. 将蛋白质合成抑制剂与蛋白酶体抑制剂结合起来,可诱导癌细胞死亡,并改善模型中的生存率.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 威尔姆斯瘤是一种常见的儿科癌.
- 扩散性形威尔姆斯瘤是一种耐化学药的亚型.
- 阿克丁诺米辛D抑制了核糖体RNA生物发生,这是癌症治疗的目标.
研究的目的:
- 为了调查威尔姆斯瘤细胞如何逃避阿克丁诺米辛D治疗.
- 确定治疗策略,以克服形威尔姆斯瘤中抗化学性.
主要方法:
- 核糖体造型分析 核糖体造型分析 核糖体造型分析
- 蛋白质阵列是一种蛋白质阵列.
- 整个基因组的淘汰屏幕.
- 在体外和体内实验实验.
- 对患者数据的分析.
主要成果:
- 乙胺 D 干扰蛋白质稳态和细胞循环的进展.
- 无塑性威尔姆斯瘤细胞高调蛋白酶体活动以抵消D.阿克丁诺米辛的作用.
- 用博特佐米布 (蛋白酶体抑制剂) 和阿克丁诺米辛D联合治疗会诱导亡并延长存活时间.
- 增加的蛋白酶组分水平与形组织学和不良预后相关.
结论:
- 维持蛋白质平衡对于威尔姆斯瘤的扩散至关重要.
- 针对蛋白质合成和循环的治疗策略可以克服化学阻力.
- 组合疗法对治疗耐化学药威尔姆斯瘤具有前景.
相关概念视频
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Destabilization of Microtubules
2.7K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.7K


